With an eye on building a global presence in prostate cancer treatment, Amersham and cryotherapy developer Galil Medical of Yokneam, Israel, have agreed to merge Amersham Health 's brachytherapy unit with Galil's urology operations. The new U.S.-based company would operate independently, with Buckinghamshire, U.K.-based Amersham holding 75% and Galil retaining 25%, the companies said.
The combined businesses generated 2002 sales of $90 million (U.S.). Subject to regulatory approvals, the deal is expected to close by the end of July.
By AuntMinnie.com staff writersApril 23, 2003
Related Reading
Mirada, Amersham to develop molecular imaging application, February 6, 2003
Amersham gets FDA approval for Irish facility, July 11, 2002
Amersham, Premier extend brachytherapy seed agreements, July 2, 2002
Amersham to market Optison in Europe, June 6, 2002
Copyright © 2003 AuntMinnie.com
